BioMed Realty Lands Full-Building Tenant Near Denver

March 5, 2026

Brokerage Denver News Office More West

A developer of peptide drugs signed the 15-year lease.

BioMed Realty has signed CordenPharma Colorado to a 15-year, 64,000-square-foot lease at 5505 Central in Boulder, Colo. CordenPharma Colorado, a developer of peptide drug substances, will occupy the entire building.

Built in 2024, the new facility is LEED Gold-certified and rises two stories with 28,000-square-foot floorplates, according to Yardi Matrix.

5505 Central is located within BioMed’s Flatiron Park office and life science campus, which comprises 25 buildings totaling more than a million square feet. The campus includes a coffee shop and brewery, along with bike sharing, nature trails and EV charging stations.

Blackstone’s BioMed Realty acquired Flatiron Park from a joint venture of Crescent Real Estate, Goldman Sachs Asset Management’s Real Estate Business and Lionstone Investments in 2022, paying the group more than $600 million for the campus. Since then, BioMed has added more buildings to the site.

Another major lease for BioMed

This is the second major domestic life science lease that BioMed has signed so far this year. In January, the firm inked TransMedics Group Inc. to a 498,000-square-foot, full-building lease at Assembly Innovation Park in Somerville, Mass., just outside Boston.

That lease agreement is for the next 16 years. In addition to signing the new lease, TransMedics purchased the adjacent land and part of the parking structure at the campus for future growth.

Denver-Boulder’s life science market

The Denver-Boulder life science market showed modest improvement by the end of 2025, according to a report from Savills. Overall vacancy was 27.1 percent at the end of the fourth quarter, down 40 basis points year-over-year. Available space declined slightly from 1.5 million square feet to 1.4 million square feet.

The metro has 300,000 square feet of life science space under construction, unchanged from 2024. Venture capital funding, meanwhile, surged 115.6 percent year-over-year to $1.7 billion across 69 deals.